LAW OFFICE
OF
LAWRENCE
W. BAILEY
P.L.L.C.

October 15, 2015

OTC Markets Group, Inc.
304 Hudson Street, Second Floor New
York, New York 10013

Re: North American Cannabis Holdings, Inc. f/k/a Algae International Group, Inc.
Opinion of Counsel regarding Adequate Current Information and Continuing
Disclosure Requirements for period ending June 30, 2015

Dear Sir or Madam:

This firm has been retained as legal counsel for North American Cannabis Holdings, Inc. (USMJ or the "Company") f/n/a Algae International Group, Inc. (ALGA), for the purpose of preparing this Opinion of Counsel, applying the applicable laws of the United States, regarding its corporate operations and level of disclosure of corporate information with regard to the OTC Markets Disclosure Guidelines. This firm is not under investigation by any federal or state regulatory authority to the best of counsel's knowledge.

In the course of preparing this opinion, counsel has reviewed the following documents relating to the Company, all of which appear to comply as to form with the OTC Pink Basic Disclosure Guidelines, (together with the date they were posted through the OTC Disclosure and News Service, if applicable):

Articles of Incorporation (as contained in Exhibit 2.1 to Form 10SB12G filed/posted October 18, 1999);
Articles/Certificate of Merger of the Company (as contained in Exhibit 2.2 to Form 10SB12G filed/posted with the SEC on October 18, 1999);
Certificate of Correction of the Company (as contained in Exhibit 2.3 to Form 10SB12G filed/posted with the SEC on October 18, 1999);
Articles of Merger of the Company (as contained in Exhibit 2.4 to Form 10SB12G filed/posted with the SEC on October 18, 1999);
By-Laws of the Company (as contained in Exhibit 2.5 to Form 10SB12G filed/posted with the SEC on October 18, 1999);
Initial Company Disclosure Statement (posted October 12, 2005)
Annual Report (Year Ended June 30, 2015; posted to OTC Markets Disclosures)
Annual Report (Year Ended June 30, 2014; posted to OTC Markets Disclosures)
Annual Report (Year Ended June 30, 2013; posted to OTC Markets Disclosures)
Quarterly Report (Quarter Ended September 30, 2014; posted to OTC Markets Disclosures)
Quarterly Report (Quarter Ended December 31,2014; posted to OTC Markets Disclosures)
Quarterly Report (Quarter Ended March 31, 2013; posted to OTC Markets Disclosures)
Other related corporate information as were necessary and provided by the corporation's management for the purposes of this letter.

17824 Misty Grove Drive
DALLAS, TEXAS 75287
PHONE:(214)641-5485
FAX: 1 (866) 278-6511
LWBAILEYESQ@AOL.COM
WWW.BAILEYHARNECK.COM

Additionally, counsel has personally met with management and the directors of the Company.

The opinions and conclusions contained in this Opinion Letter are based upon documentation and facts made available to this firm, and are solely based on the accuracy of those documents and facts. Further, counsel has reviewed all prior disclosures posted by the Company with OTC Disclosure and News Service, as amended. All such information is believed to be accurate and reliable. In the event that any of the facts and information in any or all of such documents are determined not to be true, this opinion is rescinded and shall be deemed to be null and void. Counsel has discussed the above documentation, and the underlying assumptions this firm is relying upon, with the management of the corporation.

The Company has 1,000,000,000 (One Billion) authorized shares of common stock, par value $.001 of which 149,773,693 shares of common stock are issued and outstanding as of the date hereof. The Company is authorized to issue 10,000,000 shares of preferred stock, par value $.001 of which 100,000 shares of preferred stock are issued and outstanding together with the rights, privileges, and preferences which may be set by the Board of Directors without further shareholder approval.

The party responsible for the preparation of the unaudited financial statements of USMJ:

Steven B. Rash, Chairman & CEO

Mr. Rash is a medical industry veteran with a lengthy list of career accomplishments and experiences well suited to American Seed & Oil's cannabis business strategy. Mr. Rash has negotiated medical device licensing agreements and health care partner strategic alliances that combined have generated over $650 million in new revenues. Mr. Rash has also managed numerous drug trials and secured multiple FDA approvals. He has signed over 400 managed care contracts and made more than 200 Boardroom presentations at Fortune 500 companies. Mr. Rash served as President and CEO of American BioMed, Vice President of Blue Rhino Corporation and Division President of Maxum Health Corporation. He earlier held numerous Vice President positions at BOC Group, PLC. Mr. Rash has a BS in Business Administration from the University of Delaware and an MBA from Southern Illinois University. Mr. Rash is also a Veteran of the United States Army.

The Company's Transfer Agent is:

Olde Monmouth Stock Transfer Co. 200
Memorial Pkwy.
Atlantic Highlands, NJ 07716 Phone:
732-872-2727


An inquiry to the transfer agent was the source of confirmation of the USMJ shares outstanding. Additionally, a search of the SEC's EDGAR system confirmed that Olde Monmouth Stock Transfer Co. is a registered transfer agent.

Further, to inquiry of management and directors of the corporation, to the best of this firm's knowledge, neither USMJ nor any person or entity holding at least five percent (5%) of the corporation's stock is currently under investigation by any federal or state regulatory authority for any violation of federal or state securities law. Mr. Bollen has controlling interest of North American Cannabis Holdings, Inc.

No person or entity other than OTC Markets Group is entitled to rely upon this opinion. OTC Markets Groups, however, is granted full and complete permission and rights to publish this document via the OTC Disclosure and News Service for viewing by the general public and regulators. The public and OTC Markets Group may rely on the above in determining whether USMJ has made adequate current information publicly available within the meaning of Rule 144(c)(2) of the Securities Act of 1933. However, the information which has been posted via OTC Disclosure and News Service constitutes adequate current public information, is available within the meaning of S.E.C. Rule 144(c)(2) of the Securities Act, includes all the information that a broker-dealer would be required to obtain from an issuer in order to publish a quotation for its securities pursuant to Rule 15c2-11 under the Securities Exchange Act of 1934, and complies as to form with the OTC Markets Guidelines for Providing Adequate Current Information.

The author of this letter has been admitted to practice in the State of Texas and is a resident of the United States. Counsel is permitted to practice before the Securities and Exchange Commission and has not been prohibited from practice thereunder.

Best Regards,



Lawrence, Bailey

17824 Misty Grove Drive
DALLAS, TEXAS 75287

PHONE:(214)641-5485
FAX: 1 (866) 278-6511

LWBAILEYESQ@AOL.COM
WWW.BAILEYHARNECK.COM